ECHOIQ LIMITED - AGM Information 2018

==> picture [173 x 57] intentionally omitted <==

8 June 2018

ASX Announcement

VERILUMA LIMITED

(ASX: VRI) ACN 142 901 353

(Subject to a Deed of Company Arrangement)

___________

2017 AGM – Chairman’s Address and CEO Presentation

____________

We attach the Chairman’s address and the CEO Presentation to the 2017 AGM to be held on 8 June 2018 at 10:00am.

For more information, please contact:

Investor Enquiries:

[email protected]

www.veriluma.com

About Veriluma and Prescriptive Analytics:

Veriluma has developed and patented an advanced algorithm dealing in Prescriptive Analytics. Prescriptive Analytics is a form of advanced, forward-looking analytics, which provides assessments about future outcomes. Although most types of analytics aim to assist and improve in the decision making process, only Prescriptive Analytics delivers a preferred course of action. Developed by a Commonwealth Research Centre with Australian Defence whose Intelligence Organisation has been utilising Veriluma’s technology since 2013. Veriluma’s software assists decision makers with rapid and accurate assessments of terrorism and national security threats using its patented technology.

In complex decision making situations, the ability to comprehensively manage incomplete or uncertain inputs is highly valuable for businesses, governments and individuals. Orbis Research estimates that the Artificial Intelligence/Prescriptive Analytics market is currently worth US$4.6b, and will grow over the next 5 years at a CAGR of 22%, to reach an estimated US$20b by 2020. Currently, 10% of organisations have some form of prescriptive analytics and this is expected to grow to 35% by 2020. ¹Source: Gartner Forecast Snapshot: Prescriptive Analytics, Worldwide, 2016; 5 February 2016

Veriluma’s software has wide applications across multiple industries including banking and financial services, government, defence and national security, insurance, legal, health, pharmaceutical and resources.

==> picture [173 x 57] intentionally omitted <==

8 June 2018

Dear Shareholders

Looking at the time since the last completed Annual General Meeting in November 2016, there have been a number of very significant changes in the company structure and also its financial strength and position.

As you know the company was placed into Administration by the previous Board in November of last year. Your current directors did not and do not agree with the strategy and disruption that this caused, and have worked tirelessly to ensure that the company returns to normalcy in the shortest timeframe possible.

With this objective in mind, we are pleased to put before you today, a number of resolutions that will see Veriluma well placed to forge ahead progressively.

I urge you to show strong support for your directors, and to vote unanimously in favour of each of the resolutions that you will vote on shortly.

You will note that the first resolution seeks approval for the issue of 360,167,853 shares at a price of $0.0031 to raise $1,116,520.

This is the first step on the road to recovery and will enable the company to fulfil its obligations under the Deed of Company Arrangement, to come out of Administration and to have working capital to develop and acquire new assets, if appropriate.

Two other resolutions relate to the confirmation of an appropriate Board to drive the company forward. Stability in this respect after the challenges of the last twelve months is paramount.

Finally, the last resolution relates to approval of the Remuneration Report as it was included in the last Annual Report.

As indicated in the Notice of Meeting your directors recommend that you vote in favour of all the resolutions before us today.

John Welsh Chairman Veriluma Limited.

==> picture [236 x 495] intentionally omitted <==

==> picture [358 x 98] intentionally omitted <==

2017 Annual General Meeting Friday 8 June 2018 Shareholder Update Elizabeth Whitelock

Disclaimer

This presentation is the property of Veriluma Ltd. It is a presentation of non-specific background information about the current activities of Veriluma. It is information given in summary form and does not claim to be complete.

All persons should seek appropriate professional investment advice in reviewing or considering this presentation and all other information with respect to Veriluma, its business, financial performance and operations. Neither the provision of this presentation nor the information contained therein, or any associated communication to any person should be taken as constituting financial advice regarding the purchase or dealing of shares in Veriluma. This presentation does not claim to provide all information that might reasonably be required to complete a detailed assessment of Veriluma.

Individuals should conduct their own investigation of investment and financial parameters relevant to their personal requirements for investment purposes. The presentation may contain forward looking statements regarding the intentions of the company and these will be affected by many other factors beyond the company’s control.

Forward looking statements include, but are not limited to, statements concerning Veriluma’s planned strategies and other statements that are not based on historical facts. Although Veriluma believes that its forward looking statements are reasonable, such statements involve risks, uncertainty and dependencies and no assurance can be given that results will be consistent with these forward looking statements. This presentation must be considered with regard to these risks, dependencies and uncertainty and any investment in Veriluma should be considered as speculative.

This presentation does not constitute an offer, invitation, recommendation or advice to subscribe for, or purchase any security and neither this presentation nor anything it contains shall form the basis of any contract or commitment. This presentation does not constitute an offer or invitation in any jurisdiction , or to any person where such an offer would be unlawful.

About

Veriluma’s patented Prescriptive Analytics software helps organisations decide based on decisions about situations by considering what is known from the sources that are available including observations, opinions and gut feel. Veriluma produces an assessment of the situation depicting likelihood despite uncertainty and continually changing conditions. Every assessment is self-explanatory

The prescriptive analytics market size is estimated to grow from USD 1.16 Billion in 2016 to USD 4.58 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of 31.7% during the forecast period .*

Prescriptive analytics can help prevent fraud, limit risk, increase efficiency, meet business goals and create more loyal customers. It can be used to make decisions on any time horizon, from immediate to long term.

*MarketsandMarkets Research, January 2017